Intelligence

Behavioral Health Intelligence Dashboard

Regulation, markets, pipeline status, and news signals across pharma, psychedelics, cannabis, and digital health — monitored from public sources and reviewed with editorial judgment.

How this is built →

Regulatory & Clinical Tracker

View full tracker →

Selected FDA and DEA documents from the Federal Register, and clinical-trial registrations from ClinicalTrials.gov, kept apart. Documents show their publication date and registrations the date ClinicalTrials.gov first posted them.

  • Regulatory documents: Federal Register publications from Nov 10, 2024 to Nov 17, 2026.
  • Clinical-trial registrations: first posted from Aug 12, 2026 to Nov 17, 2026.

Regulatory documents

All 410 →

FDA and DEA documents in the Federal Register. Dates shown are publication dates.

Published November 12, 2026
DEA
Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV
Interim final rule · Effective Nov 12, 2026 · Comments due Dec 14, 2026
scheduling

On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration…

Federal Register document 2026-23075

View on Federal Register
DEA
Importer of Controlled Substances Application: NSI Lab Solutions LLC
Notice · Comments due Dec 14, 2026
scheduling

NSI Lab Solutions LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Federal Register document 2026-23006

View on Federal Register
Published November 10, 2026
DEA
Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
Notice
scheduling

The Drug Enforcement Administration (DEA) proposes to establish the 2027 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine…

Federal Register document 2026-22843

View on Federal Register

Clinical-trial registrations

All 553 →

A registration is a sponsor’s listing of a study on ClinicalTrials.gov. It is not a regulatory action and does not show that a trial has results or that a treatment works. Dates shown are first-posted dates.

First posted November 17, 2026
Registration
Anxiety Reduction, Learning Support, Mood, and Self-efficacy Adaptation in Families With Healthy Newborns
Status at last check: Not yet recruiting · NCT07943936

Anxiety, Parenting Stress, Depressive Symptoms — ALMA-RN Instagram-Based Parental Education Programme

ClinicalTrials.gov registration NCT07943936 · first posted Nov 17, 2026

Status is as reported by ClinicalTrials.gov at the last verified check (Nov 17, 2026), not a real-time status.

A registration is a sponsor’s listing of a study on ClinicalTrials.gov. It is not a regulatory action and does not show that a trial has results or that a treatment works.

View on ClinicalTrials.gov
Registration
Can Spending Time in Nature Help Mothers With Depression After Childbirth? A 6-Week Forest Therapy Study
Status at last check: Enrolling by invitation · NCT07943858

Postpartum Depression, Postpartum Depression (PPD), Postnatal Depression — Forest Therapy Group, Standard Care (in control arm)

ClinicalTrials.gov registration NCT07943858 · first posted Nov 17, 2026

Status is as reported by ClinicalTrials.gov at the last verified check (Nov 17, 2026), not a real-time status.

A registration is a sponsor’s listing of a study on ClinicalTrials.gov. It is not a regulatory action and does not show that a trial has results or that a treatment works.

View on ClinicalTrials.gov
Registration
Ketamine for Treatment of Alzheimers Disease Related Depression
Status at last check: Not yet recruiting · NCT07943741

Late Life Depression (LLD), MCI, MCI-AD, Early Stage Alzheimer's Disease — Ketamine and saline, Active Placebo (Midazolam) Infusion

ClinicalTrials.gov registration NCT07943741 · first posted Nov 17, 2026

Status is as reported by ClinicalTrials.gov at the last verified check (Nov 17, 2026), not a real-time status.

A registration is a sponsor’s listing of a study on ClinicalTrials.gov. It is not a regulatory action and does not show that a trial has results or that a treatment works.

View on ClinicalTrials.gov

Tracked public-market securities, equities and ETFs, connected to behavioral health: pharma psychiatry, psychedelics, cannabis, and digital health. Open Markets for every tracked company's profile and Behavioral Wire's recent coverage of it.

HELP Helus Pharma (formerly Cybin)
Psychedelics
Profile and coverage →
$7.20 −0.47 (−6.13%)
Nov 17, 2026 22:45 UTC · Delayed quote
Historical chart unavailable for HELP from the current data provider. Latest delayed quote is still shown below.
Last
$7.20
Change
−0.47
Change %
−6.13%
Open
$7.81
Day high
$8.07
Day low
$7.03
Volume
3.01M
Market cap
$574.7M
52W range
$3.76 – $15.15

Delayed quotes. Last updated 17 Nov 2026, 22:45 UTC.

Movers

Gainers
Losers

Delayed quotes. Last updated 17 Nov 2026, 22:45 UTC.

News wire

Behavioral Wire

What moved90 days · 2
▲
COMP360 TRD
Phase 3 → Filed
‖
Remlifanserin AD psychosis
Setback at Phase 3

Movement tracking since Oct 9, 2026; 90-day history covers 4 of 29 tracks.

All changes →

Regulation & Policy

Structured records of regulatory and policy actions, built from primary government sources and organized around what changed, when decisions took effect, and what remains unresolved.

First product

Regulatory Decision & Effective-Date Record

Current corpus:U.S. Drug Enforcement Administration

Selected regulatory actions reconstructed from official government records, separating proposal, formal decision, effective date, correction, and unresolved status.

Scope

Selected Drug Enforcement Administration actions under the Controlled Substances Act, compiled from official Federal Register documents. Dates shown are those the documents themselves state. This is a curated record, not a complete account of DEA activity. Each record shows its status as of the date given. The linked Federal Register text controls.

8 records · status as of October 31, 2026

  1. Diphenidine: Schedule I placement

    IN EFFECT
    EffectiveOct 21, 2026
    DEADEA-1155

    Current status Permanently placed in Schedule I; effective October 21, 2026.

    Agency
    Drug Enforcement Administration (DEA)
    Docket
    DEA-1155
    Status as of
    October 31, 2026
    1. Published September 21, 2026 Final rule
    2. Effective October 21, 2026

    Summary

    In May 2026 DEA proposed placing diphenidine in Schedule I of the Controlled Substances Act. DEA finalized the permanent placement in a final rule published September 21, 2026. The final rule is effective October 21, 2026.

    Regulatory sequence, oldest first

    1. PROPOSAL

      Notice of proposed rulemaking

      What changedDEA opened a proposed rule. No legal change yet.

      Published
      May 26, 2026
      Comments and hearing requests due
      June 25, 2026

      91 FR 30519 · Federal Register FR Doc. 2026-10380

    2. FORMAL DECISION

      Final rule

      What changedDEA finalized permanent Schedule I placement.

      Published
      September 21, 2026
      Signed
      September 11, 2026

      Finalized from the proposed rule published May 26, 2026.

      91 FR 59695 · Federal Register FR Doc. 2026-19231

    3. EFFECTIVE

      The Schedule I placement took legal effect.

      Established by 91 FR 59695 · Federal Register FR Doc. 2026-19231

    How to cite

    Behavioral Wire. “Diphenidine: Schedule I placement” (DEA-1155). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-1155

    The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.

  2. Butalbital: removal of exempt status for inactive products

    DECIDED — NOT YET EFFECTIVE
    EffectiveNov 9, 2026
    DEADEA-1664RIN 1117-ZA08

    Current status DEA has made the final determination, but the change becomes effective November 9, 2026.

    Agency
    Drug Enforcement Administration (DEA)
    Docket
    DEA-1664
    RIN
    1117-ZA08
    Status as of
    October 31, 2026
    1. Published October 9, 2026 Final determination
    2. Effective November 9, 2026 Not yet in effect

    ImportantThis action does not schedule butalbital. It does not affect exempted prescription products with active National Drug Codes.

    Summary

    DEA is revoking the exempt status of certain nonnarcotic prescription products on its Table of Exempted Prescription Products whose National Drug Codes are inactive, because the products are no longer available and/or the company that applied for the exemption no longer exists. This action does not schedule butalbital. It does not affect exempted prescription products with active National Drug Codes. DEA signed the final determination October 6, 2026 and published it October 9, 2026; it takes effect November 9, 2026.

    Regulatory sequence, oldest first

    1. PROPOSAL

      Notice of proposed rulemaking

      What changedDEA proposed to revoke the exempt status of the specified products. No legal change yet.

      Published
      May 26, 2026
      Comments due
      June 25, 2026

      91 FR 30527 · Federal Register FR Doc. 2026-10379

    2. FORMAL DECISION

      Final determination

      What changedDEA determined that the exempt status of the specified products is revoked, effective November 9, 2026.

      Published
      October 9, 2026
      Effective
      November 9, 2026
      Signed
      October 6, 2026

      Finalized from the proposed rule; the determination cites 91 FR 30527.

      91 FR 64618 · Federal Register FR Doc. 2026-20757

    3. EFFECTIVE Not yet in effect

      The revocation takes legal effect on this date.

      Established by 91 FR 64618 · Federal Register FR Doc. 2026-20757

    How to cite

    Behavioral Wire. “Butalbital: removal of exempt status for inactive products” (DEA-1664). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-1664

    The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.

  3. O-desmethyltramadol (O-DSMT): temporary Schedule I placement

    IN EFFECT — TEMPORARYTemporary through August 12, 2028Corrected October 9, 2026
    ThroughAug 12, 2028
    DEADEA-1641

    Current status Temporary Schedule I placement remains in effect through August 12, 2028, unless extended or replaced through subsequent action.

    Agency
    Drug Enforcement Administration (DEA)
    Docket
    DEA-1641
    Status as of
    October 31, 2026
    Temporary through
    August 12, 2028
    Corrected
    October 9, 2026
    1. Published August 12, 2026 Temporary scheduling order
    2. Effective August 12, 2026
    3. Expires August 12, 2028 Temporary

    Summary

    In June 2026 DEA announced its intent to issue a temporary order placing O-desmethyltramadol (O-DSMT) in Schedule I. It issued the temporary order August 12, 2026, effective August 12, 2026 until August 12, 2028. A correcting amendment published October 9, 2026 restored omitted language concerning salts, isomers and salts of isomers in the CFR listing; it is not a new scheduling decision.

    Regulatory sequence, oldest first

    1. NOTICE

      Notice of intent to issue a temporary scheduling order

      What changedNo legal change yet; DEA announced its intent to issue a temporary scheduling order.

      Published
      June 24, 2026

      91 FR 37822 · Federal Register FR Doc. 2026-12654

    2. FORMAL DECISION EFFECTIVE Temporary

      Temporary scheduling order

      What changedDEA placed the substance temporarily in Schedule I.

      Published
      August 12, 2026
      Effective
      August 12, 2026
      Expires
      August 12, 2028
      Signed
      August 6, 2026

      Temporary order following the notice of intent; the order cites 91 FR 37822.

      91 FR 52013 · Federal Register FR Doc. 2026-16413

      CORRECTION / AMENDMENT Not a new scheduling decision

      Correcting amendment to the order above

      What was wrong
      The order's CFR listing omitted language concerning salts, isomers and salts of isomers.
      What changed
      DEA corrected 21 CFR 1308.11(h)(88) to add that language. The amendment states the placement itself was effective August 12, 2026; it does not make a new placement.
      Published
      October 9, 2026
      Correction effective
      October 9, 2026
      Applicable from
      August 12, 2026
      Expires
      August 12, 2028
      Signed
      October 6, 2026

      Corrects the August 12, 2026 order, cited as 91 FR 52013.

      The correction's official title omits “Temporary.” The placement it corrects remains temporary.

      91 FR 64617 · Federal Register FR Doc. 2026-20748

    How to cite

    Behavioral Wire. “O-desmethyltramadol (O-DSMT): temporary Schedule I placement” (DEA-1641). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-1641

    The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.

  4. 5,6-Dichloro brorphine and related substances: temporary Schedule I placement

    IN EFFECT — TEMPORARYTemporary through August 27, 2028
    ThroughAug 27, 2028
    DEADEA-1665

    Current status Temporary Schedule I placement remains in effect through August 27, 2028, unless extended or replaced through subsequent action.

    Agency
    Drug Enforcement Administration (DEA)
    Docket
    DEA-1665
    Status as of
    October 31, 2026
    Temporary through
    August 27, 2028
    1. Published August 27, 2026 Temporary scheduling order
    2. Effective August 27, 2026
    3. Expires August 27, 2028 Temporary

    Summary

    On July 1, 2026 DEA announced its intent to issue a temporary order placing four substances in Schedule I: 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine and spirochlorphine. DEA issued the temporary order August 27, 2026, effective August 27, 2026 until August 27, 2028.

    Regulatory sequence, oldest first

    1. NOTICE

      Notice of intent to issue a temporary scheduling order

      What changedNo legal change yet; DEA announced its intent to issue a temporary scheduling order.

      Published
      July 1, 2026

      No scheduling effective date is shown for this event; scheduling begins only with the order.

      91 FR 39940 · Federal Register FR Doc. 2026-13364

    2. FORMAL DECISION EFFECTIVE Temporary

      Temporary scheduling order

      What changedDEA placed the four substances temporarily in Schedule I.

      Published
      August 27, 2026
      Effective
      August 27, 2026
      Expires
      August 27, 2028
      Signed
      August 23, 2026

      Temporary order following the notice of intent; the order cites 91 FR 39940.

      91 FR 55252 · Federal Register FR Doc. 2026-17531

    How to cite

    Behavioral Wire. “5,6-Dichloro brorphine and related substances: temporary Schedule I placement” (DEA-1665). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-1665

    The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.

  5. 2-Fluorodeschloroketamine (2-FDCK): temporary Schedule I placement

    IN EFFECT — TEMPORARYTemporary through May 22, 2028
    ThroughMay 22, 2028
    DEADEA-1442

    Current status Temporary Schedule I placement remains in effect through May 22, 2028, unless extended or replaced through subsequent action.

    Agency
    Drug Enforcement Administration (DEA)
    Docket
    DEA-1442
    Status as of
    October 31, 2026
    Temporary through
    May 22, 2028
    1. Published May 22, 2026 Temporary scheduling order
    2. Effective May 22, 2026
    3. Expires May 22, 2028 Temporary

    Summary

    On January 20, 2026 DEA announced its intent to issue a temporary order placing 2-fluorodeschloroketamine (2-FDCK) in Schedule I. DEA issued the temporary order May 22, 2026, effective May 22, 2026 until May 22, 2028.

    Regulatory sequence, oldest first

    1. NOTICE

      Notice of intent to issue a temporary scheduling order

      What changedNo legal change yet; DEA announced its intent to issue a temporary scheduling order.

      Published
      January 20, 2026

      91 FR 2323 · Federal Register FR Doc. 2026-00954

    2. FORMAL DECISION EFFECTIVE Temporary

      Temporary scheduling order

      What changedDEA placed the substance temporarily in Schedule I.

      Published
      May 22, 2026
      Effective
      May 22, 2026
      Expires
      May 22, 2028
      Signed
      May 14, 2026

      Temporary order following the notice of intent; the order cites 91 FR 2323.

      91 FR 30204 · Federal Register FR Doc. 2026-10253

    How to cite

    Behavioral Wire. “2-Fluorodeschloroketamine (2-FDCK): temporary Schedule I placement” (DEA-1442). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-1442

    The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.

  6. Bromazolam: temporary Schedule I placement

    IN EFFECT — TEMPORARYTemporary through March 16, 2028Corrected June 24, 2026
    ThroughMar 16, 2028
    DEADEA-1420

    Current status Temporary Schedule I placement remains in effect through March 16, 2028, unless extended or replaced through subsequent action.

    Agency
    Drug Enforcement Administration (DEA)
    Docket
    DEA-1420
    Status as of
    October 31, 2026
    Temporary through
    March 16, 2028
    Corrected
    June 24, 2026
    1. Published March 16, 2026 Temporary scheduling order
    2. Effective March 16, 2026
    3. Expires March 16, 2028 Temporary

    Summary

    On December 15, 2025 DEA announced its intent to issue a temporary order placing bromazolam in Schedule I. It issued the temporary order March 16, 2026, effective March 16, 2026 until March 16, 2028. A correcting amendment published June 24, 2026 replaced an invalid chemical name in the CFR listing with the valid one; it is not a new scheduling decision.

    Regulatory sequence, oldest first

    1. NOTICE

      Notification of intent to issue a temporary scheduling order

      What changedNo legal change yet; DEA announced its intent to issue a temporary scheduling order.

      Published
      December 15, 2025

      90 FR 57924 · Federal Register FR Doc. 2025-22763

    2. FORMAL DECISION EFFECTIVE Temporary

      Temporary scheduling order

      What changedDEA placed the substance temporarily in Schedule I.

      Published
      March 16, 2026
      Effective
      March 16, 2026
      Expires
      March 16, 2028
      Signed
      March 10, 2026

      Temporary order following the notice of intent; the order cites 90 FR 57924.

      91 FR 12504 · Federal Register FR Doc. 2026-05064

      CORRECTION / AMENDMENT Not a new scheduling decision

      Correcting amendment to the order above

      What was wrong
      The order's chemical name for bromazolam was invalid.
      What changed
      DEA corrected 21 CFR 1308.11(h)(86) to give the valid chemical name. The amendment states the placement was effective March 16, 2026; it does not make a new placement.
      Published
      June 24, 2026
      Correction effective
      June 24, 2026
      Applicable from
      March 16, 2026
      Signed
      June 16, 2026

      Corrects the March 16, 2026 order, cited as 91 FR 12504.

      The correction's official title omits “Temporary.” The placement it corrects remains temporary.

      91 FR 37821 · Federal Register FR Doc. 2026-12653

    How to cite

    Behavioral Wire. “Bromazolam: temporary Schedule I placement” (DEA-1420). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-1420

    The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.

  7. SUPPORT Act regulations: dispensing and administering controlled substances for medication-assisted treatment

    IN EFFECT
    EffectiveJul 9, 2026
    DEADEA-499RIN 1117-AB55

    Current status The final rule is in effect since July 9, 2026.

    Agency
    Drug Enforcement Administration (DEA)
    Docket
    DEA-499
    RIN
    1117-AB55
    Status as of
    October 31, 2026
    1. Published June 9, 2026 Final rule
    2. Effective July 9, 2026

    Summary

    In November 2020 DEA issued an interim final rule amending its regulations to make them consistent with the 2018 SUPPORT Act. In June 2026 DEA published a final rule, effective July 9, 2026. It adopts the provisions of the interim final rule that are still applicable as final, with minor changes. It removes provisions the interim rule had based on statutes since repealed, and it includes provisions tied to the Restoring Hope for Mental Health and Well-Being Act of 2022.

    Official titleImplementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment.
    “Implementation” is part of the government's title; it is not a Behavioral Wire claim of operational implementation tracking.

    Regulatory sequence, oldest first

    1. FORMAL DECISION EFFECTIVE

      Interim final rule with request for comments

      What changedDEA amended its regulations to make them consistent with the 2018 SUPPORT Act, effective on an interim basis with comments invited.

      Published
      November 2, 2020
      Effective
      October 30, 2020
      Comments due
      January 4, 2021

      The document's stated effective date precedes its Federal Register publication date.

      85 FR 69153 · Federal Register FR Doc. 2020-23813

    2. FORMAL DECISION

      Final rule

      What changedDEA adopted the still-applicable interim provisions as final, with minor changes; removed provisions based on repealed statutes; and included provisions tied to the Restoring Hope Act.

      Published
      June 9, 2026
      Signed
      June 3, 2026

      Finalizes in part the interim final rule; the final rule cites it as 85 FR 69153.

      91 FR 34754 · Federal Register FR Doc. 2026-11526

    3. EFFECTIVE

      The final rule took legal effect.

      No provision-level description beyond the verified summary is asserted here. Readers should consult the linked Federal Register text.

      Established by 91 FR 34754 · Federal Register FR Doc. 2026-11526

    How to cite

    Behavioral Wire. “SUPPORT Act regulations: dispensing and administering controlled substances for medication-assisted treatment” (DEA-499). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-499

    The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.

  8. Phenethyl bromide / phenethyl halides: proposed List I chemical designation

    PROPOSAL STAGE
    Comments closedAug 10, 2026
    DEADEA-1282

    Current status Proposal stage. The comment period closed August 10, 2026; no final rule was located as of October 31, 2026.

    Agency
    Drug Enforcement Administration (DEA)
    Docket
    DEA-1282
    Status as of
    October 31, 2026
    1. Published July 9, 2026 Proposed rule
    2. Comments closed August 10, 2026

    ImportantPrecursor chemical regulation, not scheduling of a controlled substance.

    Summary

    This record concerns regulation of precursor (List I) chemicals under the Controlled Substances Act. It is not scheduling of a controlled substance. In October 2024 DEA published an advance notice asking for information on uses of phenethyl bromide before deciding whether to propose listing it. In July 2026 DEA proposed designating phenethyl halides as List I chemicals, a wider group than phenethyl bromide alone.

    Regulatory sequence, oldest first

    1. NOTICE

      Advance notice of proposed rulemaking: Possible Control of Phenethyl Bromide as a List I Chemical

      Scope: phenethyl bromide

      What changedNo legal change; DEA requested information on the uses of phenethyl bromide before deciding whether to propose listing it.

      Published
      October 28, 2024
      Comments due
      November 27, 2024

      89 FR 85459 · Federal Register FR Doc. 2024-24616

    2. PROPOSAL

      Notice of proposed rulemaking: Designation of Phenethyl Halides as List I Chemicals

      Scope: phenethyl halides

      What changedDEA opened a proposed rule; no final action has been located. If finalized, it would subject handlers of phenethyl halides to the chemical regulatory provisions of the Controlled Substances Act.

      Published
      July 9, 2026
      Comments due
      August 10, 2026 (closed)

      Cites the 2024 advance notice, 89 FR 85459.

      91 FR 42392 · Federal Register FR Doc. 2026-13825

    How to cite

    Behavioral Wire. “Phenethyl bromide / phenethyl halides: proposed List I chemical designation” (DEA-1282). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-1282

    The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.

Temporary-order end dates reflect the Federal Register action in force as of the record date. Temporary scheduling periods may be extended through subsequent agency action where authorized by law.